Related Experiment Video
Updated: Jun 23, 2026
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Bile acid-based polyaminocarboxylate conjugates as targeted antitumor agents
Hyun-Soon Chong1, Hyun A Song, Xiang Ma
1Chemistry Division, Biological, Chemical, and Physical Sciences Department, Illinois Institute of Technology, Chicago, IL, USA. chong@iit.edu
Chemical Communications (Cambridge, England)
|May 23, 2009
Summary
Bile acid-polyaminocarboxylate conjugates with NE3TA, an iron chelator, show significant cancer cell toxicity. Modified conjugates successfully entered HT29 colon cancer cells, indicating potential therapeutic applications.
Area of Science:
- Biochemistry
- Organic Chemistry
- Cancer Biology
Background:
- Bile acids are natural compounds with diverse biological roles.
- Polyaminocarboxylates are known chelating agents.
- Iron chelation is a strategy explored in cancer therapy.
Purpose of the Study:
- To synthesize and evaluate bile acid-polyaminocarboxylate conjugates containing NE3TA.
- To assess the cytotoxic effects of these conjugates on cancer cell lines.
- To investigate the cellular uptake of modified conjugates.
Main Methods:
- Synthesis of novel bile acid-NE3TA conjugates.
- Cytotoxicity assays using HeLa and HT29 colon cancer cells.
- Cellular uptake studies with fluorescently labeled conjugates.
Main Results:
- Conjugates demonstrated significant cytotoxicity against HeLa and HT29 cells.
- Cholic acid-NE3TA conjugated to a fluorophore entered HT29 cells.
- NE3TA acts as a potential iron chelator in these conjugates.
Conclusions:
- Bile acid-polyaminocarboxylate conjugates are promising cytotoxic agents.
- Targeted delivery into cancer cells was achieved.
- Further research into iron chelation and cancer therapy is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...